Nobivac Solvent

País: Irlanda

Idioma: anglès

Font: HPRA (Health Products Regulatory Authority)

Compra'l ara

Fitxa tècnica Fitxa tècnica (SPC)
12-06-2017

Disponible des:

Intervet Ireland Limited

Codi ATC:

QV07AB

Dosis:

.

formulario farmacéutico:

Solvent for parenteral use

tipo de receta:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupo terapéutico:

Cats, Dogs

Área terapéutica:

Solvents and diluting agents, incl. irrigating solutions

indicaciones terapéuticas:

Immunological - Diluent

Estat d'Autorització:

Authorised

Data d'autorització:

2003-10-03

Fitxa tècnica

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac Solvent
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCES:
None
EXCIPIENTS:
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Solvent for parenteral use.
Clear, colourless liquid.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats and dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Solvent for reconstitution of Nobivac DHP, Nobivac DHPPi, Nobivac
Parvo-C, Nobivac Ducat and Nobivac Tricat
Trio vaccines.
4.3 CONTRAINDICATIONS
Any contra-indications specified for the vaccine for which the solvent
is used for reconstitution will apply.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
There are no special warnings, however any warnings specified for the
vaccine for which Nobivac Solvent is used as
the solvent will apply.
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
No special precautions are required for handling the solvent however
any recommendations specified for the vaccine
for which Nobivac Solvent is used as a solvent will apply.
Special precautions to be taken by the person administering the
veterinary medicinal product to animals
In case of accidental self-injection, seek medical advice immediately
and show the package leaflet or the label to the
physician.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_2_
_/_
_1_
_2_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_2_
_4_
_7_
_3_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:
                                
                                Llegiu el document complet
                                
                            

Cerqueu alertes relacionades amb aquest producte

Veure l'historial de documents